ABBV - Ulcerative colitis market set to hit $9.6B by 2031

2023-04-22 16:00:00 ET

Treatments for ulcerative colitis (UC) are projected to reach $9.6B in eight major markets by 2031 driven by an increase in the patient population and new therapies coming to market.

That's the assessment from data and analytics firm GlobalData, which sees a 2.8% CAGR for UC treatments. The eight markets are US, France, Germany, Italy, Spain, the UK, Japan, and Canada.

Ulcerative colitis treatment is currently dominated by tumor necrosis factor ( TNF ) inhibitors, including AbbVie's ( NYSE: ABBV ) Humira (adalimumab), and Johnson & Johnson ( JNJ ) Janssen's unit Remicade (infliximab) and Simponi (golimumab).

Other biologics used for UC are Takeda Pharmaceutical's ( TAK ) Entyvio (vedolizumab), an integrin receptor antagonist, and Janssen's interleukin-12 and -23 antagonist Stelara (ustekinumab).

Generic steroids and immunomodulators are also used.

GlobalData Pharma analyst Ramla Salad said that TNF inhibitors and these generic drugs are unlikely to be replaced as first-line therapies. "However, the prospect of novel pipeline therapies will be welcomed as they target an underserved population of patients who do not respond adequately to current therapies."

In a new report Salad authored, "Ulcerative Colitis (UC) Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast to 2031," she noted that 11 UC therapies in the pipeline are set to enter the market in the coming years.

These include: Roivant Sciences' ( ROIV ) RVT-3101, AbbVie's ( ABBV ) Skyrizi (risankizumab), Eli Lilly's ( LLY ) mirikizumab, Janssen's Tremfya (guselkumab), Boehringer Ingelheim's spesolimab, Reistone Biopharma’s ivarmacitinib, Pfizer's ( PFE ) ritlecitinib and etrasimod, NImmune Biopharma's omilancor, Abivax’s ( OTCPK:AAVXF ) obefazimod and InDex Pharmaceuticals' cobitolimod.

Salad highlighted cobitolimod as it has a rectal route of administration. With a 2028 projected launch, she sees it as having a significant impact in the UC market. However, she cautioned that it will likely face competition from janus kinase (JAK) inhibitors ivarmacitinib and ritlecitinib that are also entering the market the same year.

"The launch of 11 pipeline products in the US prior to 2031 will create more treatment options for patients and address some of the unmet needs in the UC market to varying extents," Salad wrote . "As a result, considerable opportunity remains for players looking to enter the market in the future, particularly outside of the US."

More on UC Treatments

Immunic surges ~20% as IMU-838 shows promise in ulcerative colitis trial

AbbVie gains as Skyrizi succeeds in Phase 3 trial for ulcerative colitis

Lilly mirikizumab helps reduce ulcerative colitis symptoms in 50% patients at 1 year in trial

Pfizer's etrasimod helps improve remission in ulcerative colitis patients in phase 3 trial

Johnson & Johnson highlights long-term effect of ulcerative colitis therapy

For further details see: